The potential use of antisclerostin therapy in chronic kidney disease - Mineral and bone disorder

Current Opinion in Nephrology and Hypertension

Volumn 24, Issue 4, 2015, Pages 324-329

  Costa, Aline G ^a,b   Bilezikian, John P ^a   Lewiecki, E Michael ^c  

^a Columbia University ^*  (United States)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c New Mexico Clinical Research Osteoporosis Center   (United States)

Author keywords

Chronic kidney disease; Monoclonal antibody; Osteoporosis; Sclerostin

Indexed keywords

BLOSOZUMAB; MONOCLONAL ANTIBODY; PARATHYROID HORMONE; ROMOSOZUMAB; SCLEROSTIN; SCLEROSTIN ANTIBODY; UNCLASSIFIED DRUG; ANTIBODY; MINERAL;

BONE DENSITY; BONE DISEASE; BONE MASS; BONE MINERALIZATION; BONE TURNOVER; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY DISEASE MINERAL BONE DISORDER; HUMAN; NONHUMAN; OSSIFICATION; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; TRABECULAR BONE; WNT SIGNALING PATHWAY; ANIMAL; BONE; COMPLICATION; METABOLISM; PHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC;

ANIMALS; ANTIBODIES; BONE AND BONES; BONE DENSITY; HUMANS; MINERALS; OSTEOPOROSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84942783491     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0000000000000133     Document Type: Review

References (41)

1. Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 2006;69:1945-1953.
2. Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol 2011;6:913-921.
3. Moorthi RN, Moe SM. CKD-mineral and bone disorder: core curriculum 2011. Am J Kidney Dis 2011;58:1022-1036.
4. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 2009;76(Suppl 113):S1-S130.
5. Viaene L, Behets GJ, Claes K, et al. Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis? Nephrol Dial Transplant 2013;28:3024-3030.
6. Thompson B, Towler DA. Arterial calcification and bone physiology: role of the bone-vascular axis. Nat Rev Endocrinol 2012;8:529-543.
7. Koos R, Brandenburg V, Mahnken AH, et al. Sclerostin as a potential novel biomarker for aortic valve calcification: an in-vivo and ex-vivo study. J Heart Valve Dis 2013;22:317-325.
8. Lu KC, Wu CC, Yen JF, Liu WC. Vascular calcification and renal bone disorders. ScientificWorldJournal 2014;2014:637065. doi: 10.1155/2014/637065.
9. Costa AG, Bilezikian JP, Lewiecki EM. Update on romosozumab: a humanized monoclonal antibody to sclerostin. Expert Opin Biol Ther 2014;14:697-707.
10. Van Bezooijen RL, Roelen BA, Visser A, et al. Sclerostin is an osteocyteexpressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 2004;199:805-814.
11. Krause C, Korchynskyi O, De Rooij K, et al. Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways. J Biol Chem 2010;285:41614-41626.
12. Li X, Zhang Y, Kang H, et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 2005;280:19883-19887.
13. Semenov M, Tamai K, He X. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem 2005;280:26770-26775.
14. Van Bezooijen RL, Svensson JP, Eefting D, et al. Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J Bone Miner Res 2007;22:19-28.
15. Johnson ML, Kamel MA. The Wnt signaling pathway and bone metabolism. Curr Opin Rheumatol 2007;19:376-382.
16. Gardner JC, Van Bezooijen RL, Mervis B, et al. Bone mineral density in sclerosteosis; affected individuals and gene carriers. J Clin Endocrinol Metab 2005;90:6392-6395.
17. Van Lierop AH, Hamdy NA, Hamersma H, et al. Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover. J Bone Miner Res 2011;26:2804-2811.
18. Li X, Ominsky MS, Niu QT, et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 2008;23:860-869.
19. Costa AG, Cremers S, Dworakowski E, et al. Comparison of two commercially available ELISAs for circulating sclerostin. Osteoporos Int 2014;25:1547-1554.
20. Drake MT, Srinivasan B, Modder UI, et al. Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab 2010;95:5056-5062.
21. Pelletier S, Dubourg L, Carlier MC, et al. The relation between renal function and serum sclerostin inadult patients with CKD. Clin J AmSoc Nephrol 2013;8:819-823.
22. Cejka D, Herberth J, Branscum AJ, et al. Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol 2011;6:877-882.
23. Desjardins L, Liabeuf S, Oliveira RB, et al. Uremic toxicity and sclerostin in chronic kidney disease patients. Nephrol Ther 2014;10:463-470.
24. Cejka D, Marculescu R, Kozakowski N, et al. Renal elimination of sclerostin increases with declining kidney function. J Clin Endocrinol Metab 2014;99:248-255.
25. Bonani M, Rodriguez D, Fehr T, et al. Sclerostin blood levels before and after kidney transplantation. Kidney Blood Press Res 2014;39:230-239.
26. Costa AG, Walker MD, Zhang CA, et al. Circulating sclerostin levels and markers of bone turnover in Chinese-American and white women. J Clin Endocrinol Metab 2013;98:4736-4743.
27. Lapauw B, Vandewalle S, Taes Y, et al. Serum sclerostin levels in men with idiopathic osteoporosis. Eur J Endocrinol 2013;168:615-620.
28. Ishimura E, Okuno S, Ichii M, et al. Relationship between serum sclerostin, bone metabolism markers, and bone mineral density in maintenance hemodialysis patients. J Clin Endocrinol Metab 2014;99:4315-4320.
29. Marinou K, Christodoulides C, Antoniades C, Koutsilieris M. Wnt signaling in cardiovascular physiology. Trends Endocrinol Metab 2012;23:628-636.
30. Hamersma H, Gardner J, Beighton P. The natural history of sclerosteosis. Clin Genet 2003;63:192-197.
31. Kanbay M, Siriopol D, Saglam M, et al. Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients. J Clin Endocrinol Metab 2014;99:E1854-E1861. First study to study to show the association between sclerostin and all causes of mortality and cardiovascular events in CKD patients.
32. Fahrleitner-Pammer A, Herberth J, Browning SR, et al. Bone markers predict cardiovascular events in chronic kidney disease. J Bone Miner Res 2008;23:1850-1858.
33. Drechsler C, Evenepoel P, Vervloet MG, et al. High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant 2015;30:288-293. doi: 10.1093/ndt/gfu301.
34. Padhi D, Jang G, Stouch B, et al. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2011;26:19-26.
35. Padhi D, Allison M, Kivitz AJ, et al. Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: A randomized, double-blind, placebo-controlled study. J Clin Pharmacol 2014;54:168-178. doi: 10.1002/jcph.239.
36. Graeff C, Campbell G, Peña J, et al. Effects of romosozumab administration on trabecular and cortical bone assessed with quantitative computed tomography and finite element analysis. Presented at the European Calcified Tissue Society Conference ECTS 18-21 May 2013, Lisbon, Portugal. Bone Abstracts 1 OC5.4. doi: 10.1530/boneabs.01. OC5.4.
37. McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal & women with low bone mineral density. N Engl J Med 2014;370:412-420. Phase II trial of romosozumab, a humanized sclerostin antibody.
38. McColm J, Hu L, Womack T, et al. Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women. J Bone Miner Res 2014;29:935-943. doi: 2.
39. Recker R, Benson C, Matsumoto T, et al. A randomized, double-blind phase 2 & clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Min Res 2015;30:216-224. doi: 10.1002/jbmr.2351. Data of phase 2 trial of blosozumab, a humanized sclerostin antibody.
40. Moe SM, Chen NX, Newman CL, et al. Anti-sclerostin antibody treatment in a & rat model of progressive renal osteodystrophy. J Bone Miner Res 2015;30:499-509. doi: 10.1002/jbmr.2372. Scl-Ab preclinical trial in a rat model of CKD-MB.
41. Fang Y, Ginsberg C, Seifert M, et al. CKD-induced wingless/integration1 inhibitors and phosphorus cause the CKD-mineral and bone disorder. J Am Soc Nephrol 2014;25:1760-1773.